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Abstract 
The ubiquitin (Ub) proteasome system and ubiquitin signalling networks are crucial to cell 
biology and disease development. Deubiquitylases (DUBs) control cell signalling by 
removing mono-Ub and poly-Ub chains from substrates. DUBs take part in almost all 
processes that regulate cellular life and are frequently dysregulated in disease. We have 
catalogued 99 currently known DUBs in the human genome and sequence conservation 
analyses of catalytic residues suggest that 11 lack enzyme activity and are classed as 
pseudo-DUBs. These pseudoenzymes play important biological roles by allosterically 
activating catalytically competent DUBs as well as other active enzymes. Additionally, 
pseudoenzymes act as assembly scaffolds of macromolecular complexes. We discuss 
how pseudo-DUBs have lost their catalytic activity, their diverse mechanisms of action, 
and their potential as therapeutic targets. Many known pseudo-DUBs play crucial roles in 
cell biology and it is likely that unstudied and overlooked pseudo-DUB genes will have 
equally important functions.   
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Introduction 
Ubiquitylation of proteins serves as a post-translational signal to regulate virtually all 
cellular processes through the precise spatial and temporal control of protein stability, 
activity and/or localisation [1]. Enzymes involved in the ubiquitin system are frequently 
dysregulated in cancer, neurodegeneration, autoimmunity and other human diseases [2-5]. 
Ubiquitylation is a versatile post-translational modification aptly suited for a cellular 
communication system, with the essential Òwriter, reader and eraserÓ core signalling 
modules (Fig. 1).   
 
Ubiquitin processing enzymes (E1, E2 and E3) write the ubiquitin signalling code by 
adding ubiquitin to substrates (writer module). A single ubiquitin (Ub) can be conjugated to 
lysine residues on the surface of substrate proteins (this is known as mono-ubiquitylation), 
or conjugated further to lysine residues on the surface of Ub itself, thus leading to poly-Ub 
chains. Seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) and the free amino 
terminus (M1) on Ub can be targeted for poly-ubiquitylation, and thus eight different Ub 
chain types can be generated in total, all having different topologies and unique signalling 
properties [3]. Ubiquitin chains can be Òread outÓ by ubiquitin binding domains (UBDs), 
which allow signal decoding and transmission (reader module). Ubiquitylation is a 
reversible process, and removal of Ub is carried out by deubiquitylating (DUB) enzymes 
(eraser module). DUB actions allow the cell to produce monomeric Ub, recycle Ub from 
chains and reverse signalling events resulting from ubiquitylation [6,7]. To date, 99 DUBs 
have been identified in the human genome, comprising six major structural families, 
namely (1) the ubiquitin-specific proteases (USPs), (2) the ubiquitin C-terminal hydrolyses 
(UCHs), (3) the Machado-Joseph domain proteases (Josephins), (4) the ovarian tumour 
proteases (OTUs), (5) the Jab1/MPN/Mov34 metalloproteases (JAMM/MPNs) and (6) the 
newly discovered MIU-containing novel DUB family proteases (MINDYs) (Fig. 2) [8,9]. 
 
The JAMM/MPN family is unique in using zinc during catalysis, whereas all other DUBs 
are cysteine proteases. Cysteine-dependent DUBs contain a common catalytic triad with a 
cysteine, a histidine and an acidic residue, although their structural folds differ markedly 
from one another [6,10]. Nevertheless, four of the DUB families (USPs, UCHs, Josephins 
and OTUs) can be assigned to the papain-like structural fold, according to Pfam and 
SCOP databases. Representative structures for each DUB family have been reported and 
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our understanding of how the families function as proteases has greatly improved in 
recent years [10]. However, fundamental questions remain as to how DUB function is 
regulated (i.e. switched on and off) and how substrate specificity is controlled. For 
example, while some DUBs display exquisite selectivity for specific ubiquitin chain types in 
vitro and in vivo, others appear highly promiscuous, at least in vitro. Similarly, the catalytic 
and non-catalytic functions of some DUBs are highly regulated, while others appear 
constitutively active or permanently repressed (e.g. pseudo-DUBs). This variability of 
function is underpinned by diverse regulatory molecular mechanisms, even within the 
same structural family. As such, DUBs represent a fascinating family of enzymes that 
require a close inspection of mechanism of action as well as biological function.  
 
Overview of pseudoenzymes and pseudo-DUBs 
The past 10-15 years have seen a surge in studies showing how pseudoenzymes 
(enzymes predicted to lack catalytic activity) employ innovative and unexpected 
mechanisms to regulate biological functions. Pseudoenzymes perform these important 
roles by allosterically activating catalytically competent enzymes, acting as crucial 
scaffolds and as molecular switches. The best studied pseudoenzymes are 
pseudokinases, which have been covered in numerous reviews [11-15]. Around 50 proteins 
containing the kinase fold have been classed as pseudokinases, representing 
approximately 10% of the human kinome [16]. While some predicted pseudokinases have 
shown vestigial kinase activity in vitro, the majority are classed as true pseudokinases with 
no catalytic activity, and perform important biological roles as pseudoenzymes. It is now 
clear that almost every enzyme family contains some inactive ÒrogueÓ members. The 
precise fraction may vary depending on the enzyme class, but in the relatively small 
number of families studied, approximately 5-15% of proteins are inactive pseudoenzymes 
[17-20]. This is true for pseudokinases, pseudoproteases, pseudo-E2 ubiquitin ligases and 
pseudo-DUBs [21-23]. 
 
The human genome contains 99 known DUBs (Fig. 2) and this number is likely to 
increase as new members and families are discovered [9]. Of the 99 known DUB proteins, 
11 are predicted to be catalytically inactive pseudoenzymes and classed as pseudo-
DUBs. Interestingly, the number of pseudo-DUBs differs widely for each family, and two 
families, namely UCH and Josephins, have no pseudo-DUBs. The JAMM/MPN family 
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contains the largest number (seven pseudo-DUBs), followed by the USP family with two 
inactive pseudo-DUBs, whilst the OTU and MINDY families each contain one pseudo-DUB 
(Fig. 2). Despite the lack of catalytic residues, pseudo-DUBs perform regulatory roles in 
many biological functions, such as gene expression and regulation [24-26], DNA damage 
repair [27-29], protein turnover [30,31], cytokine signalling and immune responses [32].  
 
DUBÐpseudo-DUB heterodimers 
The JAMM/MPN family of DUBs contains 14 members in humans. They share a common 
metalloprotease domain architecture, denoted the MPN domain, harbouring a zinc 
chelating active site [33-35]. Seven out of the 14 family members are predicted to be 
catalytically active (denoted MPN+), while the others, which bear substitutions to essential 
catalytic residues, are predicted to be catalytically dead (denoted MPNÐ). MPN family 
proteases typically function within larger multi-subunit complexes, which imparts great 
potential for multi-layer regulation.  
 
The MPN family DUBs regulate diverse aspects of cellular biology, most notably DNA 
repair through BRCC36 (MPN+) in the BRCA1-A complex (BRCC36-ABRAXAS1-
BRCC45-MERIT40-RAP80 complex) [29,36-38], interferon receptor signalling through 
BRCC36 (MPN+) in the BRISC-SHMT2 complex (BRCC36-ABRAXAS2-BRCC45-
MERIT40 complex) [32,39] (Fig. 3), and protein degradation through Rpn11/PSMD14 
(MPN+) in the proteasome lid complex [40]. The CSN5-CSN6 MPN+ÐMPNÐ pair is part of 
the Cop9 signallosome (CSN) complex that deneddylates cullin proteins modified with the 
ubiquitin-like (UBL) small protein NEDD8. Thus, CSN5 is a deneddylase rather than a 
DUB.  
 
Interestingly, many of the MPNÐ pseudo-DUBs directly interact with active MPN+ domains 
to form stable heterodimers (Fig. 4). In a remarkable analogy to kinase-pseudokinase 
heterodimers where a pseudokinase allosterically activates a kinase [12,41,42], some 
pseudo-DUBs also allosterically activate DUBs (Fig. 4A and 5A).  
 
BRCC36-ABRAXAS1 and BRCC36-ABRAXAS2 (BRCC36-KIAA0157)  
The active DUB BRCC36 (MPN+) is found in two macromolecular complexes in the cell 
(Fig. 3), depending on which partnering MPNÐ pseudo-DUB it interacts with (ABRAXAS1 
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or ABRAXAS2). The BRCC36-ABRAXAS1 complex translocates to the nucleus via the 
ABRAXAS1 nuclear localisation signal (NLS) and is part of a larger DUB complex called 
the BRCA1-A complex. This complex localises to sites of DNA damage (e.g. a double 
strand break) through RAP80 anchoring to K63-linked poly-Ub chains (Fig. 3). Therefore, 
the BRCA1-A complex plays at least two roles that ultimately lead to DNA damage repair: 
(1) binding and cleaving K63-linked polyubiquitin chains (poly-Ub) and (2) recruitment of 
BRCA1 to sites of DNA damage. 
 
In the cytoplasm, BRCC36 interacts with ABRAXAS2 (a.k.a. KIAA0157) and is part of a 
larger complex called BRISC-SHMT2 (Fig. 3). This cytoplasmic DUB complex interacts 
with and deubiquitylates interferon receptors 1 and 2 (IFNAR1/2) and prevents the 
receptors from being prematurely endocytosed and entering the lysosomal degradation 
pathway. Thus, the BRISC-SHMT2 complex regulates interferon-dependent immune 
response by stabilising the interferon receptors and ensuring their availability at the 
membrane [32].  
BRISC deficiency in mice due to genetic deletion of the BRISC specific pseudo-DUB 
ABRAXAS2 resulted in resistance to bacterial lipopolysaccharide [32]. Interestingly, the 
mice did not display any adverse phenotypes or deficiency in the DNA damage response, 
raising the possibility that inhibitors of pseudo-DUB function in the BRISC may have 
clinical utility against disease processes stemming from elevated inflammatory cytokine 
signals. 
 
Biochemical studies demonstrated that BRCC36 is inactive in isolation and that 
heterodimerisation with the pseudo-DUB ABRAXAS2 was required for DUB activity [43-45]. 
The crystal structure and biochemical studies of BRCC36-ABRAXAS2 (a.k.a. BRCC36-
KIAA0157) provided insights into the mechanism of BRCC36 activation [45]. BRCC36 
forms an obligate heterodimer with ABRAXAS2 and interactions are mediated via MPN 
domains and C-terminal helices from both proteins. The C-terminal helical bundle 
participates in higher-order interactions to form a dimer of heterodimers (super dimer), 
which constitutes the minimally active assembly capable of cleaving Lys63-linked poly-Ub 
chain substrates (Fig. 4A and 5A). A forced BRCC36-BRCC36 homodimer was also 
observed by X-ray crystallography, however the BRCC36 active site residues in this 
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crystal structure were not optimally positioned for catalysis (Fig. 5A). Instead, BRCC36 
requires direct interactions with ABRAXAS2 to attain an active conformation (Fig. 5A) [45].  
 
The JAMM motif is typical of MPN domain containing proteases and is required for 
catalysis. It contains five conserved residues from four key structural motifs, namely:  
1) E-loop, which houses a glutamic acid residue (E30, Fig. 4A). Its role is to coordinate a 
catalytic water molecule. 
2) H-strand, which houses the His-X-His motif with two histidine residues (H94 and H96, 
Fig. 4A) involved in Zn2+ binding.  
3) S-loop, which houses a serine residue (S104, Fig. 4A) involved in stabilising the 
transition state intermediate. 
4) D-helix, which houses an aspartic acid residue (D107, Fig. 4A) involved in Zn2+ binding. 
 
ABRAXAS1 and 2 both have several changes in the JAMM motif that preclude function as 
an active DUB, with changes in the E-loop, H-strand and D-helix (Supp. Fig. 1). The 
structure of BRCC36-ABRAXAS2 complex revealed that ABRAXAS2 is incapable of 
interacting with Zn2+ and is therefore a pseudo-DUB [45]. Structural comparison of active 
BRCC36 with the pseudo-DUB ABRAXAS2 revealed that while there are non-conservative 
changes in the active site residues, the overall MPN fold and the position of the JAMM 
motif residues are the same for both active and inactive MPN domains (Fig. 4A). As a 
result, the MPN fold maintains its structural integrity, despite the loss of Zn2+ and several 
changes to conserved catalytic residues. Interestingly, the positive charge lost by the 
absence of the Zn2+ ion is compensated by a guanidinium group from Arg103 
(ABRAXAS2) which replaces the Zn2+-interacting His96 (BRCC36) residue (Fig. 4A). 
 
The biochemical and structural data thus far support the notion that ABRAXAS2 and the 
related pseudo-DUB ABRAXAS1 serve as allosteric activators of BRCC36 and have a 
non-catalytic role as molecular scaffolds for the correct assembly of BRCA1-A and BRISC-
SHMT2 complexes.   
 
Rpn11-Rpn8 (PSMD14-PSMD7 in humans) 
Yeast Rpn11 and Rpn8 (PSMD14 and PSMD7 respectively, in humans) are part of the 
19S regulatory particle of the proteasome and play a key role in ubiquitin processing and 
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recycling. The MPN+ domain protein Rpn11 removes poly-Ub chains from ubiquitylated 
substrates before they translocate to the 20S proteasome. Similar to BRCC36, Rpn11 
partners with the pseudo-DUB Rpn8 (Fig. 4B), and is part of a larger macromolecular 
complex. Rpn8 supports the role of Rpn11 through direct interactions and is required for 
full Rpn11 catalytic activity [31,46].  
 
The yeast pseudo-DUB Rpn8 contains three notable changes in catalytic residues: E-loop 
(Glu to Arg), H-strand (His-X-His motif changed to His-X-Gly) and S-loop (Ser to Arg). 
Changes in the H-X-H motif render Rpn8 incapable of binding the catalytic Zn2+ (Fig. 4B). 
Interestingly, the overall fold and integrity of the MPN domain remains unaffected by 
compensating interactions in the form of a salt bridge between Asp103 (D-loop) and Arg32 
(E-loop), and Arg100 (S-loop) hydrogen bonding with a backbone carbonyl group from the 
E-loop.  
Collectively, these active site residue changes abrogate Rpn8 catalytic activity. It is still 
unclear if Rpn8 allosterically activates Rpn11 or if its main role is to stabilise the Rpn11 
fold within the multiprotein complex. 
 
CSN5-CSN6 
The COP9 signalosome (CSN complex) has eight subunits amounting to approximately 
450 kDa [47]. CSN5, the active protease subunit, removes Nedd8 from cullins and thus 
regulates the activity of cullin RING E3 ligases [48,49]. CSN5 and CSN6 proteins are 
overexpressed in many cancers, and the Cop9 signalosome is implicated in Ub-mediated 
degradation of several cancer related genes: p27, p53, Mdm2, Smad7, Runx3, Id1, Skp2 
and HIF1 [50]. Despite the fact that CSN5 is not specific for cleaving ubiquitin, CSN5 
(MPN+) and CSN6 (MPN−) heterodimers are similar in topology to Rpn11-Rpn8 complexes 
(Fig. 4B, C and 5B) and represent a recurring theme in MPN domain heterodimerisation.  
 
The pseudo-DUB CSN6 contains four notable changes in the E-loop (Glu to Gln), H-strand 
(His-X-His motif changed to Thr-X-Gly) and S-loop (Ser to Asn). Changes in the H-X-H 
motif render CSN6 incapable of binding the catalytic Zn2+ (Fig. 4C). Interestingly, the 
position of the D-helix remains unchanged by compensating interactions between Asp135 
and Lys153 from a neighbouring β-strand. This ensures minimal disruption to the CSN6 
MPN fold in the absence of the Zn2+ ion.  
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Collectively, these active site residue changes abrogate CSN6 catalytic activity. It is still 
unclear if CSN6 allosterically activates CSN5 or if its main role is to stabilise the CSN5 fold 
within the multiprotein complex. 
 
Heterodimerisation of CSN5-CSN6, Rpn11-Rpn8 and eIF3f-eIF3h (discussed below) are 
topologically similar to each other, but differ from the heterodimer formed by BRCC36-
ABRAXAS2 (Fig. 4 left panels and Fig. 5). This may be because BRCC36-ABRAXAS1/2 
require further assembly into a dimer of heterodimers (super dimer), which represents the 
active form of the enzyme (Fig. 4A and 5A) [45]. This diverse mode of activation could be 
exploited to develop selective BRCC36 inhibitors by targeting the dimerisation and higher 
order super-dimerisation sites, instead of the common MPN+ active site.  
 
Pseudo-DUBs as scaffolding modules of large complexes 
Pseudo-DUBs can also act as molecular scaffolds of many macromolecular complexes, 
which are central to cellular biology. Examples include the spliceosome, eukaryotic 
initiation factor 3 (eIF3) complex and the RNA deadenylating complex Pan2-Pan3 (Fig. 6).  
 
Prp8 and USP39 
Splicing of pre-mRNA is an essential process performed by the spliceosome complex and 
a crucial step in gene expression and protein translation. Correct processing of introns 
from pre-mRNAs requires a high degree of accuracy and the spliceosome machinery is 
highly regulated. The pseudoenzyme Prp8 is central to the assembly of this large 
multiproteinÐnucleic acid complex (Fig. 6A). Prp8 is a large protein (human Prp8 has 
2335 amino acids) and contains four different inactive pseudoenzyme domains: (1) a 
restriction endonuclease (RE) homology domain (pseudo-RE), (2) a reverse transcriptase 
(RT) homology domain (pseudo-RT), (3) an RNaseH homology domain (pseudo-RNAseH) 
and (4) an MPNÐ domain (pseudo-DUB). Each of these domains has a role in binding to 
either a protein or nucleic acid component of the spliceosome. 
 
The Prp8 MPNÐ domain contains two active site residue changes, one in the E-loop (Glu 
changed to Gln) and the other in the H-strand (His-X-His motif changed to His-X-Gln). It 
was shown that the single His to Gln change in the H-X-H motif of yeast Prp8p is sufficient 
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to completely abolish Zn2+ binding [51,52] and potentially catalysis, however the Prp8 MPNÐ 
domain retains the ability to interact with Ub [53]. It is as yet unclear if the Prp8 pseudo-
DUB domain has other roles in the spliceosome beyond acting as a macromolecular 
scaffold. 
 
Interestingly, the spliceosome complex also contains the pseudo-DUB USP39 (Sad1 in 
yeast) [54], although the role of this pseudoenzyme in the splicing reaction is not clear. 
Mutations in the active site of key catalytic residues (Cys to Asp and His to Ser) render 
USP39 inactive (Supp. Fig. 2). Similarly, yeast Sad1 is devoid of catalytic activity, 
although Sad1 is still capable of interacting with ubiquitin [55]. As with the Prp8 MPNÐ 
domain the exact biological role of Sad1 ubiquitin interaction is not clear, although they 
could serve as readers of ubiquitin signalling by interacting with ubiquitin and/or ubiquitin 
chains.  
 
eIF3f-eIF3h complex 
eIF3f and eIF3h are MPNÐ domain pseudo-DUBs that are part of the eukaryotic initiation 
factor 3 (eIF3) complex. Binding of initiation factors is required to initiate protein synthesis 
and recruit transfer and messenger RNAs to the 40S subunit before assembly of active 
ribosomes. eIF3 is involved in both ribosome biogenesis and protein synthesis [56]. The full 
eIF3 complex consists of 13 subunits and amounts to approximately 800 kDa [57]. 
Interestingly, eIF3 displays a significant degree of similarity with the CSN complex and 
both contain an MPNÐMPN heterodimeric core. In the eIF3 complex, eIF3f and eIF3h are 
pseudoenzymes with their main role thought to be of a scaffolding nature (Fig. 6B). Both 
eIF3f and eIF3h are involved in direct binding to other members of the eIF3 complex and 
although they are devoid of catalytic activity, their scaffolding roles are essential [57,58]. 
 
The pseudo-DUB eIF3f contains five notable residue changes in the catalytic motifs: E-
loop (Glu to Arg), H-strand (His-X-His motif changed to Ala-X-Gly), S-loop (Ser to Thr) and 
D-Helix (Asp to Ser). Changes in the H-X-H motif and D-helix render eIF3f incapable of 
binding the catalytic Zn2+ and therefore inactive.  
 
The pseudo-DUB eIF3h also contains five notable residue changes in the catalytic motifs: 
E-loop (Glu to Val), H-strand (His-X-His motif changed to Gln-X-Thr), S-loop (Ser changed 
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to Thr) and D-Helix (Asp to Leu). Similar to eIF3f, changes in the H-X-H motif and D-helix 
render eIF3h incapable of binding the catalytic Zn2+ and inactive.  
 
Taken together, active site amino acid substitutions in eIF3f and eIF3h, which collectively 
abrogate catalytic function,	suggest their primary function is to serve as molecular scaffolds 
for assembly of the eIF3 complex.  
 
USP52/Pan2 
The yeast Pan2-Pan3 deadenylating complex takes part in shortening of poly(A) tails of 
mRNA [59]. The Pan2 orthologue in humans is the pseudo-DUB USP52 and many of the 
functions are evolutionarily conserved. USP52 was recently described as an important 
regulator of the HIF1A-mediated hypoxic response, by regulating Hif1A mRNA stability [24].  
 
USP52/Pan2 lack the catalytic cysteine (Cys mutated to Ala) and histidine (His mutated to 
Ser) residues required for DUB activity and are classed as pseudo-DUBs. However, Pan2 
contains a catalytically active RNAse domain fused to the pseudo-DUB domain (Fig. 6C). 
Interestingly, Pan3 contains a pseudokinase domain that dimerises, resulting in a Pan2-
Pan3 complex with 1:2 stoichiometry (Fig. 6C). Dimerisation of the Pan3 pseudokinase 
and the interactions of the Pan2 pseudo-DUB domain are both required for RNAse activity 
and biological function [60,61]. Furthermore, it is possible that USP52 binds Ub and acts as 
a Ub binding domain and a reader of Ub signalling.  
 
Predicted Pseudo-DUBs with unknown functions  
 
FAM105A 
FAM105A is an OTU domain containing protein that is closest to OTULIN (a.k.a. 
FAM105B or Gumby) (Fig. 2). The latter is an active DUB, which specifically cleaves 
Met1-linked linear Ub chains involved in cellular signalling [62,63]. FAM105A lacks the 
catalytic cysteine residue, which has been mutated to an Asp (Supp. Fig. 3). FAM105A is 
conserved as an inactive pseudo-DUB in vertebrate species, including mammals, birds, 
frogs and a turtle species (Pelodiscus sinensis), where the active site Cys is replaced by 
Asp or Ser (data not shown). Therefore, FAM105A is a predicted pseudo-DUB, the 
function of which remains to be identified. Interestingly, the Drosophila genome contains 
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two OTU domain pseudo-DUBs, although these are related to OTUD4 and involved in 
regulation of apoptosis [64]. Similar pseudo-OTUD4 proteins are found in the tunicate 
Ciona and in the brachiopod Lingula. 
 
MINDY4B 
The MINDY DUB family was only recently identified and contains four members, MINDY1-
4 [9]. MINDY DUBs are active against K48-linked poly-Ub chains, displaying exquisite 
specificity [9]. Interestingly, a previously unannotated member (MINDY4B) is predicted to 
have the same fold, but lacks all three catalytic residues (Supp. Fig. 4). MINDY4B 
appears conserved as an inactive pseudo-DUB across vertebrates as well as in some 
invertebrates, for example in the tunicate Ciona intestinalis, in the aphid Acyrthosiphon 
pisum and in the crab Limulus polyphemus. The function of MINDY4B predicted pseudo-
DUBs remains unknown.    
 
Evolution of pseudo-DUBs 
One striking observation is that 50% of JAMM/MPN DUBs are classed as pseudo-DUBs, 
leading to questions as to how these evolved. A possible explanation is that most JAMMs 
have a propensity to function as dimers with examples of JAMM/MPN functional dimers 
observed in many eukaryotes (e.g. yeast, ants, rodents, humans), as well as archaea [65]. 
It is possible that after gene duplication events, accumulation of mutations in active site 
residues of one protomer are tolerated, since dimerisation ensures at least 50% enzyme 
activity is always present. Over time, the supporting role as an allosteric activator or as a 
scaffolding protein may be more important than catalytic activity, thus leading to the 
evolution of pseudoenzymes. This would represent a gain in evolutionary terms, since 
repurposing an established fold may be more advantageous than creating a new one.  
 
Pseudo-DUBs as drug targets 
Given that many pseudo-DUBs take part in influencing major cellular functions, including 
activity of the proteasome (Rpn11-Rpn8), protein synthesis (Prp8 and USP52), Cop9 
signallosome (CSN5-CSN6), DNA damage repair (ABRAXAS1) and interferon signalling 
(ABRAXAS2), they present an opportunity for therapeutic intervention in disease 
conditions. Developing inhibitors of active DUBs represents challenges, since compounds 
that target JAMM domain DUBs have so far only targeted the active site Zn2+ moiety [66,67], 
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rendering them relatively non-specific. Similarly, many compounds that target other DUB 
families react with the active site cysteine [4,68]. Therefore, developing small molecule 
inhibitors against pseudo-DUBs by exploiting their allosteric mode of action rather than 
their active site, may be a more selective way of inhibiting active DUB complexes such as 
Rpn11-Rpn8, CSN5-CSN6 and BRCC36-ABRAXAS1/2.      
 
Concluding remarks 
The DUB families, like most other enzyme families, contain a fraction of pseudoenzyme 
members that lack catalytic activity. These pseudo-DUBs have important biological 
functions involved in cell signalling, protein turnover and Ub recycling. Despite their lack of 
catalytic activity, they have evolved different ways to influence cell signalling and cell 
biology. One key observation is the various mechanisms of action that pseudo-DUBs 
employ, in many cases still influencing ubiquitin signalling systems by partnering with 
active DUBs. Pseudo-DUBs are often found as part of large macromolecular complexes 
where they act as allosteric activators of other enzymes, but also as molecular scaffolds 
required for complex assembly.  
 
While the roles of most pseudo-DUBs are known, many questions still remain. For 
instance, what is the functional relevance of Prp8 and USP39/Sad1 interaction with 
ubiquitin? Do other pseudo-DUBs retain ubiquitin binding ability and ubiquitin chain 
selectivity, thereby acting as readers of ubiquitin signalling? Pseudo-DUBs that interact 
with mono-ubiquitin or poly-Ub chains may still have the same effect as active DUBs 
through a Òsubstrate trappingÓ mechanism. For instance, recent studies  show that alanine 
substitutions of active site residues can convert DUBs into avid ubiquitin-binding domains 
[69]. By interacting with Ub or poly-Ub, pseudo-DUBs can sterically hinder binding of other 
proteins that act as readers of ubiquitin signals, thus reversing the signal in the same way 
that an active DUB can by removing Ub.  
 
Finally, some pseudo-DUBs like FAM105A and MINDY4B remain unstudied with no 
assigned functional roles, despite their evolutionary conservation. As new DUBs continue 
to be discovered, the pseudo-DUB field is also likely to see additional new members. 
These have the potential to reveal new mechanisms of action of how pseudoenzymes 
work as well as important functional and biological insights.  
	 14	
 
Acknowledgements  
We thank Roger Greenberg, Richard Bayliss and Derek Ceccarelli for critically reading of 
this manuscript and useful discussions. Our work on pseudoenzymes is supported by a 
Sir Henry Dale Fellowship from the Wellcome Trust and the Royal Society 
(200523/Z/16/Z) to E.Z., and a grant from the Polish National Science Centre 
(2014/15/B/NZ1/03359) to K.P.  
 
  
	 15	
FIGURE LEGENDS 
Figure 1. Overview of ubiquitin signalling 
Ubiquitin signalling can employ the writer, reader and eraser modules as communication 
tools in a signalling network.     
 
Figure 2. Catalogue of known human DUBs and pseudo-DUBs 
Known DUB families are shown as phylogenetic trees (PhyML) [70] with pseudo-DUBs 
highlighted in red. USP17 is a highly polymorphic gene with around 30 copies as a result 
of a megasatellite repeat in chromosomes four and eight. Since these genes are almost 
identical, they are represented by USP17-L2. USP, ubiquitin-specific protease; OTU, 
ovarian tumour protease; JAMM, JAB1/MPN/MOV34 (MPN, Mpr1/Pad1 N-terminal); UCH, 
ubiquitin C-terminal hydrolase; Josephin (a.k.a. Machado-Joseph disease proteases); 
MINDY, MIU-containing novel DUB family. Gene symbols from the HUGO Gene 
Nomenclature Committee database (http://www.genenames.org/) are shown where 
possible. Trees were visualized using the Interactive Tree of Life (iTOL v3) tool accessible 
online at: https://itol.embl.de).  
 
Figure 3. BRCC36 functions as part of two distinct protein complexes 
Illustration of the BRCC36 deubiquitylase (DUB) functions. Cytoplasmic BRCC36 
regulates interferon receptor signalling as part of the BRISC complex. Nuclear BRCC36 
takes part in DNA damage repair as the active DUB in the BRCA1-A complex. Pseudo-
DUBs ABRAXAS1 and ABRAXAS2 are the main determinants for BRCC36 complex 
formation and subcellular localisation.  
 
Figure 4. Heterodimerisation of DUBs with inactive pseudo-DUBs 
Cartoon representation of active DUBs (blue) in complex with inactive pseudo-DUBs 
(pink).  
Left panels: Comparison of MPN+ÐMPNÐ modes of heterodimerisation between (A) 
BRCC36-ABRAXAS2(KIAA0157) (PDBid 5CW3), (B) Rpn11-Rpn8 (PDBid 4O8X) and (C) 
CSN5-CSN6 (PDBid 4D10).  
Right panels: Zoom in view of the superimposed MPN+ active site regions with the same 
region of MPNÐ counterparts. Amino acid side chains are shown as sticks, except glycine 
residues which are depicted as spheres. Atom colours are as follows: nitrogen = blue, 
oxygen = red, sulphur = yellow.   
 
Figure 5. Mechanism of MPN domain heterodimerisation 
A) Cartoon representation of BRCC36 allosteric activation by ABRAXAS2. In the absence 
of ABRAXAS2, BRCC36 exists in a forced homodimer (left panel) with a disordered active 
site (depicted as dashed lines) and unstructured C-terminus (not shown). Binding of 
ABRAXAS2 orders the active site regions and ensures catalytic residues are in optimal 
position. ABRAXAS2 C-terminus interacts with BRCC36 C-terminus leading to a helical 
bundle which causes the formation of an active super-dimer.     
 
B) Cartoon representation of various MPN domain heterodimerisation. Rpn11-Rpn8, 
CSN5-CSN6 and eIF3f-eIF3h heterodimers are similar to each other but differ from the 
BRCC36-ABRAXAS2 heterodimer and are not known to form higher order super-dimers.  
 
Figure 6. Pseudo-DUBs as molecular scaffolds 
	 16	
A) S. cerevisiae spliceosome structure (U4/U6.U5 tri-snRNP complex; PDBid 5GAN). 
Prp8 is represented as ribbons and transparent surface. Prp8 contains four 
pseudoenzyme domains: MPNÐ domain (pseudo-DUB), restriction endonuclease (RE) 
homology domain (pseudo-RE); reverse transcriptase (RT) homology domain (pseudo-
RT) and RNaseH homology domain (pseudo-RNAseH).  
B) Structure of eIF3 complex (PDBid 5A5T). Pseudo-DUBs eIF3f and eIF3h contain an 
MPNÐ domain and are represented as ribbons and transparent surface.      
C) Structure of Pan2-Pan3 deadenylase complex (PDBid 4XR7). Pan2 contains a UCH-
like domain as a pseudo-DUB and is represented as ribbons and transparent surface. The 
pseudokinase Pan3 forms a homodimer.  
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1. Multiple sequence alignment of JAMM/MPN DUB family 
Multiple sequence alignment (black = conserved, white = not conserved) of human 
JAMM/MPN domain DUBs. Alignments were performed using Promals3D with use of 
selected 3D structures [1] and displayed using ALINE [2]. The secondary structure of AMSH 
(PDBid 2ZNV) was determined by the program DSSP [3] and is depicted in magenta. Large 
insertions and deletions are not included in the alignment. Residues important for catalysis 
are highlighted in cyan and mutated active site residues in red.  
 
Supplementary Figure 2. Multiple sequence alignment of a subset of USP DUB family 
Multiple sequence alignment (black = conserved, white = not conserved) of a selected 
subset of human USP domain DUBs. Alignments were performed using Promals3D with 
use of selected 3D structures [1] and displayed using ALINE [2]. Large insertions and 
deletions are not included in the alignment. Residues important for catalysis are highlighted 
in cyan and mutated active site residues in red.  
 
Supplementary Figure 3. Multiple sequence alignment of OTU DUB family 
Multiple sequence alignment (black = conserved, white = not conserved) of human OTU 
domain DUBs. Alignments were performed using Promals3D with use of selected 3D 
structures [1] and displayed using ALINE [2]. The secondary structure of OTULIN (PDBid 
4KSJ) was determined by the program DSSP [3] and is depicted in magenta. Large 
insertions and deletions are not included in the alignment. Residues important for catalysis 
are highlighted in cyan and mutated active site residues in red.  
 
Supplementary Figure 4. Multiple sequence alignment of MINDY DUB family 
Multiple sequence alignment (black = conserved, white = not conserved) of human MINDY 
DUBs. Alignments were performed using Promals3D with use of selected 3D structures [1] 
and displayed using ALINE [2]. The secondary structure of MINDY1 (PDBid 5JQS) was 
determined by the program DSSP [3] and is depicted in magenta. Large insertions and 
deletions are not included in the alignment. Residues important for catalysis are highlighted 
in cyan and mutated active site residues in red.  
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